speb/financial-data huggingface dataset:
Financial ratios for CG.TO — quarterly report dated 2025-03-31
Total revenue: 209439860.13986015
Gross profit: 53522377.62237763
Operating income: 30979020.97902098
Net income: 21296503.4965035
Capital expenditures: 33962937.062937066
Operating cash flow: 40986713.28671329
Depreciation & amortization: 17390209.790209793
Net tangible assets: 1161134965.034965
Owner earnings: 4723776.223776221
Return on net tangible assets (%): 0.4068240442345111
Capex to operating income (%): 109.63205417607224
Buffett classification: The Gruesome
Stock price: 6.230769230769231
P/E ratio: 14.525858179959938
Shares outstanding: 198595055
Book value: 1161134965.034965
P/B ratio: 1.0656814197647226
Market cap (USD): 1237399958.0769231
Debt to equity: 0.01175001791712112
Current ratio: 3.201425611430315
Quick ratio: 2.4909556617684445
Effective tax rate (%): 44.90755816057021
Interest coverage ratio: 11.44702842377261
COGS to revenue (%): 74.44498979963204
SG&A to revenue (%): 4.376976216948971
Free cash flow (dilution-adjusted): 6446153.846153846
Buyback yield (%): 0.8431281304616444
Retained earnings: 579341258.7412587
Inventory turnover: 0.9973027978440273
Receivables turnover: 1.8993138349145147
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 2.2207862585967737
FCF margin (%): 3.0778066036948366
Rule of 40 score: 3.0778066036948366
Financial ratios for CG.TO — quarterly report dated 2025-06-30
Total revenue: 210469343.0656934
Gross profit: 63823357.66423357
Operating income: 50062043.795620434
Net income: 50053284.67153284
Capital expenditures: 36962043.795620434
Operating cash flow: 18470802.91970803
Depreciation & amortization: 19617518.24817518
Net tangible assets: 1243594890.510949
Owner earnings: 32708759.12408758
Return on net tangible assets (%): 2.6301779923403124
Capex to operating income (%): 73.83247065684915
Buffett classification: The Good
Stock price: 7.0437956204379555
P/E ratio: 19.605706121441646
Shares outstanding: 198595055
Book value: 1243594890.510949
P/B ratio: 1.1248542345448942
Market cap (USD): 1398862978.6496348
Debt to equity: 0.011478965208587065
Current ratio: 3.4582014895222155
Quick ratio: 2.5940926821768615
Effective tax rate (%): -3.244602366828269
Interest coverage ratio: 16.7935847208619
COGS to revenue (%): 69.67569873379968
SG&A to revenue (%): 4.302861522561671
Free cash flow (dilution-adjusted): -20162773.722627737
Buyback yield (%): 1.4105303494671921
Retained earnings: 647043795.6204379
Inventory turnover: 0.8312851704733533
Receivables turnover: 1.5788542830234136
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 3.3659268187586924
FCF margin (%): -9.57991003769816
Revenue growth (%): 0.49154106823113086
Rule of 40 score: -9.088368969467028
Financial ratios for CG.TO — quarterly report dated 2025-09-30
Total revenue: 284289928.057554
Gross profit: 98152517.98561151
Operating income: 66169784.17266188
Net income: 210207194.24460432
Capital expenditures: 45296402.87769785
Operating cash flow: 116297122.30215828
Depreciation & amortization: 25967625.899280578
Net tangible assets: 1395289208.6330936
Owner earnings: 190878417.26618704
Return on net tangible assets (%): 13.68020451137744
Capex to operating income (%): 68.45481429938245
Buffett classification: The Good
Stock price: 10.618705035971223
P/E ratio: 7.489859752640981
Shares outstanding: 198595055
Book value: 1395289208.6330938
P/B ratio: 1.5113872433037783
Market cap (USD): 2108822310.647482
Debt to equity: 0.00908607173572741
Current ratio: 2.888201504813786
Quick ratio: 2.095825355303255
Effective tax rate (%): 16.937535712356688
Interest coverage ratio: 30.78179384203481
COGS to revenue (%): 65.47450039603909
SG&A to revenue (%): 4.617082064869433
Free cash flow (dilution-adjusted): 65156834.53237411
Buyback yield (%): 0.7522354668017239
Retained earnings: 840546762.5899282
Inventory turnover: 0.8805735464789787
Receivables turnover: 2.052677509337129
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 3.9659067242678083
FCF margin (%): 22.919149819188537
Revenue growth (%): 35.07426968535704
Rule of 40 score: 57.99341950454557
Financial ratios for CG.TO — annual report dated 2025-12-31
Total revenue: 1010629197.0802919
Gross profit: 338535036.49635035
Operating income: 229508759.12408757
Net income: 426268613.1386861
Capital expenditures: 216369343.0656934
Operating cash flow: 254475912.40875912
Depreciation & amortization: 84405839.41605839
Net tangible assets: 1503475912.408759
Owner earnings: 294305109.4890511
Return on net tangible assets (%): 19.574980021963704
Capex to operating income (%): 94.27498274639264
Buffett classification: The Gruesome
Stock price: 14.343065693430654
P/E ratio: 6.682316812588613
Shares outstanding: 198595055
Book value: 1503475912.4087589
P/B ratio: 1.8945843406908178
Market cap (USD): 2848461920.255474
Debt to equity: 0.009122898664991393
Current ratio: 2.394427873610157
Quick ratio: 1.647699836429829
Effective tax rate (%): 20.11173642897596
Interest coverage ratio: 217.44605809128632
COGS to revenue (%): 66.50254737599329
SG&A to revenue (%): 5.16820481856356
Free cash flow (dilution-adjusted): 22089051.094890505
Buyback yield (%): 2.400809043665497
Retained earnings: 986235036.4963503
Inventory turnover: 2.7591477757967127
Receivables turnover: 7.910200816979461
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 12.518259203653873
FCF margin (%): 2.1856731587317864
Revenue growth (%): 18.99515701688816
Rule of 40 score: 21.180830175619946
Financial ratios for CG.TO — quarterly report dated 2025-12-31
Total revenue: 293107299.270073
Gross profit: 119259854.01459853
Operating income: 79975182.48175181
Net income: 140709489.0510949
Capital expenditures: 97994160.5839416
Operating cash flow: 75228467.15328467
Depreciation & amortization: 20289781.021897808
Net tangible assets: 1503475912.408759
Owner earnings: 63005109.48905109
Return on net tangible assets (%): 4.190629791208887
Capex to operating income (%): 122.53071208221529
Buffett classification: The Gruesome
Stock price: 14.343065693430654
P/E ratio: 6.745650229774639
Shares outstanding: 198595055
Book value: 1503475912.4087589
P/B ratio: 1.8945843406908178
Market cap (USD): 2848461920.255474
Debt to equity: 0.009122898664991393
Current ratio: 2.394427873610157
Quick ratio: 1.647699836429829
Effective tax rate (%): 25.14900540108177
COGS to revenue (%): 59.31187851288858
SG&A to revenue (%): 6.922055897419295
Free cash flow (dilution-adjusted): -30584671.53284671
Buyback yield (%): 0.7607640052550597
Retained earnings: 986235036.4963503
Inventory turnover: 0.7136958182880602
Receivables turnover: 2.2941525980518183
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 4.362143161711749
FCF margin (%): -10.43463319030673
Revenue growth (%): 3.101541891675434
Rule of 40 score: -7.333091298631296
Financial ratios for CLW — annual report dated 2021-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 36.67
Shares outstanding: 16125253
Market cap (USD): 591313027.51
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for CLW — annual report dated 2022-12-31
Total revenue: 1195000000
Gross profit: 212500000
Operating income: 100900000
Net income: 46000000
Capital expenditures: 33500000
Operating cash flow: 150200000
Depreciation & amortization: 40600000
Net tangible assets: 572000000
Owner earnings: 53100000
Return on net tangible assets (%): 9.283216783216783
Capex to operating income (%): 33.201189296333
Buffett classification: The Good
Stock price: 37.81
P/E ratio: 13.25425686804348
Shares outstanding: 16125253
Book value: 572000000
P/B ratio: 1.0659017761013987
Market cap (USD): 609695815.9300001
Debt to equity: 1.0101398601398601
Current ratio: 1.8791666666666667
Quick ratio: 0.8407051282051282
Effective tax rate (%): 35.653235653235654
Interest coverage ratio: 8.698275862068966
COGS to revenue (%): 82.21757322175732
SG&A to revenue (%): 9.280334728033472
Free cash flow (dilution-adjusted): 104000000
Buyback yield (%): 0.820081074752538
Retained earnings: 576800000
Inventory turnover: 3.0324074074074074
Receivables turnover: 6.329449152542373
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 7.251167804527488
FCF margin (%): 8.702928870292887
Rule of 40 score: 8.702928870292887
Financial ratios for CLW — annual report dated 2023-12-31
Total revenue: 1136000000
Gross profit: 200700000
Operating income: 80100000
Net income: 107700000
Capital expenditures: 73700000
Operating cash flow: 190700000
Depreciation & amortization: 40700000
Net tangible assets: 627200000
Owner earnings: 74700000
Return on net tangible assets (%): 11.910076530612244
Capex to operating income (%): 92.0099875156055
Buffett classification: The Gruesome
Stock price: 36.12
P/E ratio: 5.408023568802228
Shares outstanding: 16125253
Book value: 668700000
P/B ratio: 0.871009628174069
Market cap (USD): 582444138.36
Debt to equity: 0.6705548078360999
Current ratio: 1.9723776223776224
Quick ratio: 1.4087412587412587
Effective tax rate (%): 25.76219512195122
Interest coverage ratio: 6.965217391304348
COGS to revenue (%): 82.33274647887325
SG&A to revenue (%): 10.589788732394366
Free cash flow (dilution-adjusted): 107100000
Buyback yield (%): 3.0732560980700057
Retained earnings: 684500000
Inventory turnover: 5.802109181141439
Receivables turnover: 11.833333333333334
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 5.780054841968537
FCF margin (%): 9.42781690140845
Revenue growth (%): -4.937238493723849
Rule of 40 score: 4.490578407684601
Financial ratios for CLW — quarterly report dated 2024-09-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 28.54
Shares outstanding: 16125253
Market cap (USD): 460214720.62
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for CLW — quarterly report dated 2024-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 29.77
Shares outstanding: 16125253
Market cap (USD): 480048781.81
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for CLW — annual report dated 2024-12-31
Total revenue: 1383600000
Gross profit: 76100000
Operating income: -41000000
Net income: 196300000
Capital expenditures: 116600000
Operating cash flow: 61400000
Depreciation & amortization: 69800000
Net tangible assets: 801600000
Owner earnings: 149500000
Return on net tangible assets (%): 18.650199600798402
Buffett classification: The Gruesome
Stock price: 29.77
P/E ratio: 2.445485388741722
Shares outstanding: 16125253
Book value: 854500000
P/B ratio: 0.5617890951550614
Market cap (USD): 480048781.81
Debt to equity: 0.3432416617905208
Current ratio: 1.702247191011236
Quick ratio: 0.897003745318352
Interest coverage ratio: -1.3486842105263157
COGS to revenue (%): 94.4998554495519
SG&A to revenue (%): 8.405608557386527
Free cash flow (dilution-adjusted): -60800000
Buyback yield (%): 2.083121628242759
Retained earnings: 880800000
Inventory turnover: 5.067829457364341
Receivables turnover: 7.328389830508475
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -3.017368266117162
FCF margin (%): -4.394333622434229
Revenue growth (%): 21.795774647887324
Rule of 40 score: 17.401441025453096
Financial ratios for CLW — quarterly report dated 2025-03-31
Total revenue: 378200000
Gross profit: 36700000
Operating income: 5200000
Net income: -6300000
Capital expenditures: 32700000
Operating cash flow: 1500000
Depreciation & amortization: 22000000
Net tangible assets: 784100000
Owner earnings: -17000000
Return on net tangible assets (%): -2.168090804744293
Capex to operating income (%): 628.8461538461538
Buffett classification: The Gruesome
Stock price: 25.37
Shares outstanding: 16125253
Book value: 836500000
P/B ratio: 0.4890587789719068
Market cap (USD): 409097668.61
Debt to equity: 0.35014943215780037
Current ratio: 1.664223850766156
Quick ratio: 0.8004663557628248
Interest coverage ratio: 1.5294117647058822
COGS to revenue (%): 90.29613960867266
SG&A to revenue (%): 7.535695399259651
Free cash flow (dilution-adjusted): -32200000
Buyback yield (%): 2.66440041983988
Retained earnings: 874500000
Inventory turnover: 1.317007327419977
Receivables turnover: 2.1307042253521127
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 0.38989277948564144
FCF margin (%): -8.514013749338973
Rule of 40 score: -8.514013749338973
Financial ratios for CLW — quarterly report dated 2025-06-30
Total revenue: 391800000
Gross profit: 43000000
Operating income: 14500000
Net income: 2700000
Capital expenditures: 22900000
Operating cash flow: -28200000
Depreciation & amortization: 23000000
Net tangible assets: 785500000
Owner earnings: 2800000
Return on net tangible assets (%): 0.35646085295989816
Capex to operating income (%): 157.93103448275863
Buffett classification: The Gruesome
Stock price: 27.24
P/E ratio: 40.671471455555555
Shares outstanding: 16125253
Book value: 836700000
P/B ratio: 0.524981345428469
Market cap (USD): 439251891.71999997
Debt to equity: 0.4074339667742321
Current ratio: 1.9687379390196835
Quick ratio: 0.8730219992280973
Effective tax rate (%): 34.54545454545455
Interest coverage ratio: 3.717948717948718
COGS to revenue (%): 89.02501276161307
SG&A to revenue (%): 6.891271056661561
Free cash flow (dilution-adjusted): -53600000
Buyback yield (%): 0.9561711808579484
Retained earnings: 877300000
Inventory turnover: 1.2286016202888341
Receivables turnover: 2.361663652802893
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 1.0495078170237406
FCF margin (%): -13.68044920877999
Revenue growth (%): 3.5959809624537287
Rule of 40 score: -10.084468246326262
Financial ratios for CLW — quarterly report dated 2025-09-30
Total revenue: 399000000
Gross profit: 18800000
Operating income: -4900000
Net income: -53300000
Capital expenditures: 18300000
Operating cash flow: 34000000
Depreciation & amortization: 23700000
Net tangible assets: 780300000
Owner earnings: -47900000
Return on net tangible assets (%): -6.1386646161732665
Buffett classification: The Gruesome
Stock price: 20.76
Shares outstanding: 16125253
Book value: 783000000
P/B ratio: 0.42753544352490425
Market cap (USD): 334760252.28000003
Debt to equity: 0.4443167305236271
Current ratio: 2.0993975903614457
Quick ratio: 0.8808089500860585
Interest coverage ratio: -1.0888888888888888
COGS to revenue (%): 95.28822055137844
SG&A to revenue (%): 5.939849624060151
Free cash flow (dilution-adjusted): 15100000
Buyback yield (%): 0.6273146186553591
Retained earnings: 823900000
Inventory turnover: 1.3425141242937852
Receivables turnover: 2.469059405940594
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -0.3686982693754703
FCF margin (%): 3.7844611528822054
Revenue growth (%): 1.8376722817764166
Rule of 40 score: 5.622133434658622
Financial ratios for CLW — quarterly report dated 2025-12-31
Total revenue: 386400000
Gross profit: 17200000
Operating income: -2500000
Net income: 38400000
Capital expenditures: 14900000
Operating cash flow: 5000000
Depreciation & amortization: 23700000
Net tangible assets: 823200000
Owner earnings: 47200000
Return on net tangible assets (%): 5.733722060252672
Buffett classification: The Gruesome
Stock price: 17.4
P/E ratio: 1.8266888164062498
Shares outstanding: 16125253
Book value: 825300000
P/B ratio: 0.3399726186841149
Market cap (USD): 280579402.2
Debt to equity: 0.4342663273960984
Current ratio: 2.432932469935245
Quick ratio: 1.1299722479185939
Effective tax rate (%): -32
Interest coverage ratio: -0.5319148936170213
COGS to revenue (%): 95.54865424430642
SG&A to revenue (%): 5.331262939958592
Free cash flow (dilution-adjusted): -9600000
Buyback yield (%): 0
Retained earnings: 862300000
Inventory turnover: 1.3106141285055024
Receivables turnover: 1.977482088024565
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -0.18220246337730486
FCF margin (%): -2.484472049689441
Revenue growth (%): -3.1578947368421053
Rule of 40 score: -5.6423667865315466
Financial ratios for CLW — annual report dated 2025-12-31
Total revenue: 1555400000
Gross profit: 115600000
Operating income: 12200000
Net income: -18600000
Capital expenditures: 88800000
Operating cash flow: 12300000
Depreciation & amortization: 92400000
Net tangible assets: 823200000
Owner earnings: -15000000
Return on net tangible assets (%): -1.8221574344023324
Capex to operating income (%): 727.8688524590164
Buffett classification: The Gruesome
Stock price: 17.4
Shares outstanding: 16125253
Book value: 825300000
P/B ratio: 0.3399726186841149
Market cap (USD): 280579402.2
Debt to equity: 0.4342663273960984
Current ratio: 2.432932469935245
Quick ratio: 1.1299722479185939
Interest coverage ratio: 0.7393939393939394
COGS to revenue (%): 92.56782821139257
SG&A to revenue (%): 6.416355921306415
Free cash flow (dilution-adjusted): -80300000
Buyback yield (%): 6.130172017309973
Retained earnings: 862300000
Inventory turnover: 5.111111111111111
Receivables turnover: 7.960081883316274
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 0.8891480212812478
FCF margin (%): -5.162659123055162
Revenue growth (%): 12.416883492338826
Rule of 40 score: 7.254224369283664
Financial ratios for CSTE — annual report dated 2021-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 11.07
Shares outstanding: 34577075
Market cap (USD): 382768220.25
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for CSTE — annual report dated 2022-12-31
Total revenue: 196251704.54545453
Gross profit: 46376420.45454545
Operating income: 3732670.4545454546
Net income: -16013068.181818182
Capital expenditures: 5053693.181818182
Operating cash flow: -6622443.181818182
Depreciation & amortization: 10325000
Net tangible assets: 118430965.9090909
Owner earnings: -10741761.363636363
Return on net tangible assets (%): -9.070061432988627
Capex to operating income (%): 135.39082121927086
Buffett classification: The Gruesome
Stock price: 5.71
Shares outstanding: 34577075
Book value: 121860511.36363636
P/B ratio: 1.620172901300621
Market cap (USD): 197435098.25
Debt to equity: 0.41574872537294644
Current ratio: 2.472106386073801
Quick ratio: 1.0281360616787083
Interest coverage ratio: 2.2946210268948657
COGS to revenue (%): 76.36890820288185
R&D to revenue (%): 0.59322009362976
SG&A to revenue (%): 21.13589053945681
Free cash flow (dilution-adjusted): -12106250
Buyback yield (%): 0
Retained earnings: 88590625
Inventory turnover: 2.2144842002753617
Receivables turnover: 6.88430913348946
Capitalized R&D asset: 1164204.5454545454
ROCI (R&D-adjusted, %): 2.680482017243855
FCF margin (%): -6.168736229853245
Rule of 40 score: -6.168736229853245
Financial ratios for CSTE — annual report dated 2023-12-31
Total revenue: 156141160.22099447
Gross profit: 25397513.812154695
Operating income: -12391988.950276243
Net income: -29739226.519337017
Capital expenditures: 3036187.8453038675
Operating cash flow: 18378176.79558011
Depreciation & amortization: 8289226.519337016
Net tangible assets: 86588397.79005525
Owner earnings: -24486187.845303867
Return on net tangible assets (%): -28.278832349657044
Buffett classification: The Gruesome
Stock price: 3.74
Shares outstanding: 34577075
Book value: 89184530.38674034
P/B ratio: 1.450007752905392
Market cap (USD): 129318260.5
Debt to equity: 0.45223139062345125
Current ratio: 2.6393176212434932
Quick ratio: 1.5137391419120134
Interest coverage ratio: -8.410011248593925
COGS to revenue (%): 83.7342608597193
R&D to revenue (%): 0.8998091045961739
SG&A to revenue (%): 23.302331259255062
Free cash flow (dilution-adjusted): 15009944.751381215
Buyback yield (%): 0
Retained earnings: 56257182.32044198
Inventory turnover: 3.4687128974099646
Receivables turnover: 6.781578442194173
Capitalized R&D asset: 2184989.421145153
ROCI (R&D-adjusted, %): -9.189563048855028
Rosenberg metric: -18.019949092536717
FCF margin (%): 9.613060854765573
Revenue growth (%): -20.43831640462003
Rule of 40 score: -10.825255549854456
Financial ratios for CSTE — quarterly report dated 2024-09-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 4.56
Shares outstanding: 34577075
Market cap (USD): 157671462
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for CSTE — annual report dated 2024-12-31
Total revenue: 121430410.95890412
Gross profit: 26486301.369863015
Operating income: -9215616.438356165
Net income: -10698630.136986302
Capital expenditures: 2836712.328767123
Operating cash flow: 8732602.739726027
Depreciation & amortization: 4694246.575342466
Net tangible assets: 75607945.20547946
Owner earnings: -8841095.89041096
Return on net tangible assets (%): -11.69334236816454
Buffett classification: The Gruesome
Stock price: 4.25
Shares outstanding: 34577075
Book value: 75009589.0410959
P/B ratio: 1.9591171026078855
Market cap (USD): 146952568.75
Debt to equity: 0.49911792099640223
Current ratio: 2.2973208164126366
Quick ratio: 1.5549483149622914
Interest coverage ratio: -8.113121080559576
COGS to revenue (%): 78.18808224339551
R&D to revenue (%): 1.1168243381969716
SG&A to revenue (%): 28.284309633343184
Free cash flow (dilution-adjusted): 5317534.2465753425
Buyback yield (%): 0
Retained earnings: 45096164.38356165
Inventory turnover: 3.0774272038647
Receivables turnover: 5.090573925827237
Capitalized R&D asset: 2681683.375274351
ROCI (R&D-adjusted, %): -8.218975750199867
Rosenberg metric: 0.7749530001777657
FCF margin (%): 4.379079511124247
Revenue growth (%): -22.230364634771817
Rule of 40 score: -17.85128512364757
Financial ratios for CSTE — quarterly report dated 2024-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 4.25
Shares outstanding: 34577075
Market cap (USD): 146952568.75
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for CSTE — quarterly report dated 2025-03-31
Total revenue: 26980487.80487805
Gross profit: 5737127.371273713
Operating income: -3069647.6964769647
Net income: -3490514.9051490515
Capital expenditures: 441734.4173441735
Operating cash flow: -4088888.888888889
Depreciation & amortization: 927913.2791327913
Net tangible assets: 71718699.18699187
Owner earnings: -3004336.0433604335
Return on net tangible assets (%): -4.189055403148404
Buffett classification: The Gruesome
Stock price: 2.43
Shares outstanding: 34577075
Book value: 70848509.48509486
P/B ratio: 1.1859429769327279
Market cap (USD): 84022292.25
Debt to equity: 0.435682837918992
Current ratio: 2.216268270803652
Quick ratio: 1.4560511318663922
COGS to revenue (%): 78.73601317824786
R&D to revenue (%): 1.443379738443922
SG&A to revenue (%): 31.19789469454991
Free cash flow (dilution-adjusted): -4655284.552845528
Buyback yield (%): 0
Retained earnings: 41087262.872628726
Inventory turnover: 0.6801266756322937
Receivables turnover: 0.7545816974639602
Capitalized R&D asset: 389430.89430894307
ROCI (R&D-adjusted, %): -2.664189784660289
FCF margin (%): -17.254263846200203
Rule of 40 score: -17.254263846200203
Financial ratios for CSTE — quarterly report dated 2025-06-30
Total revenue: 29829793.510324482
Gross profit: 5860471.97640118
Operating income: -3130973.4513274333
Net income: -5473156.3421828905
Capital expenditures: 1039528.02359882
Operating cash flow: -2914159.292035398
Depreciation & amortization: 1048672.5663716814
Net tangible assets: 74380235.98820059
Owner earnings: -5464011.799410029
Return on net tangible assets (%): -7.34605332561303
Buffett classification: The Gruesome
Stock price: 1.97
Shares outstanding: 34577075
Book value: 73406784.66076697
P/B ratio: 0.9279365397188656
Market cap (USD): 68116837.75
Debt to equity: 0.4750471169263288
Current ratio: 2.173079506677056
Quick ratio: 1.3968347798049277
COGS to revenue (%): 80.35362874914708
R&D to revenue (%): 1.2727074948330253
SG&A to revenue (%): 28.86979223322093
Free cash flow (dilution-adjusted): -4070206.4896755163
Buyback yield (%): 0
Retained earnings: 39189675.51622419
Inventory turnover: 0.7031620484951279
Receivables turnover: 0.7642422043864024
Capitalized R&D asset: 640564.7168861069
ROCI (R&D-adjusted, %): -2.6661828707065074
Rosenberg metric: 0.31673040565090654
FCF margin (%): -13.644769241418867
Revenue growth (%): 10.560615975709977
Rule of 40 score: -3.08415326570889
Financial ratios for CSTE — quarterly report dated 2025-09-30
Total revenue: 30849546.827794563
Gross profit: 5327794.561933534
Operating income: -3636253.776435045
Net income: -5464350.453172205
Capital expenditures: 872205.4380664652
Operating cash flow: -871903.3232628398
Depreciation & amortization: 1042598.1873111782
Net tangible assets: 70491842.90030211
Owner earnings: -5293957.703927492
Return on net tangible assets (%): -7.5100288006583
Buffett classification: The Gruesome
Stock price: 1.59
Shares outstanding: 34577075
Book value: 69383987.91540785
P/B ratio: 0.7923665229076771
Market cap (USD): 54977549.25
Debt to equity: 0.4952995937490476
Current ratio: 2.0716778892400716
Quick ratio: 1.3551463515184827
COGS to revenue (%): 82.72974772798496
R&D to revenue (%): 1.5561344406142275
SG&A to revenue (%): 27.5011751801943
Free cash flow (dilution-adjusted): -1838368.580060423
Buyback yield (%): 0
Retained earnings: 34733836.858006045
Inventory turnover: 0.8100667408231368
Receivables turnover: 0.7983550034010148
Capitalized R&D asset: 862935.4499410833
ROCI (R&D-adjusted, %): -3.2942040946931184
Rosenberg metric: -1.4030896931199062
FCF margin (%): -5.959142901911626
Revenue growth (%): 3.418573169529756
Rule of 40 score: -2.5405697323818703
Financial ratios for CSTE — quarterly report dated 2025-12-31
Total revenue: 29696540.880503144
Gross profit: 4593710.691823899
Operating income: -5479245.2830188675
Net income: -27652830.188679244
Capital expenditures: 861635.2201257861
Operating cash flow: -3200000
Depreciation & amortization: 1185220.1257861634
Net tangible assets: 45534591.19496855
Owner earnings: -27329245.28301887
Return on net tangible assets (%): -60.018646408839786
Buffett classification: The Gruesome
Stock price: 1.86
Shares outstanding: 34577075
Book value: 43777672.95597483
P/B ratio: 1.4690904097318502
Market cap (USD): 64313359.5
Debt to equity: 0.9779761947519271
Current ratio: 1.831661528218044
Quick ratio: 1.1493696353872653
COGS to revenue (%): 84.53115899825276
R&D to revenue (%): 1.441202943823794
SG&A to revenue (%): 32.47842431301954
Free cash flow (dilution-adjusted): -3523270.440251572
Buyback yield (%): 0
Retained earnings: 8500943.396226415
Inventory turnover: 0.8467462211614957
Receivables turnover: 1.5126057150179397
Capitalized R&D asset: 874911.0906080415
ROCI (R&D-adjusted, %): -6.625334004571967
Rosenberg metric: -1.5291489050112606
FCF margin (%): -11.864245248054218
Revenue growth (%): -3.7375134024743386
Rule of 40 score: -15.601758650528556
Financial ratios for CSTE — annual report dated 2025-12-31
Total revenue: 124914465.40880503
Gross profit: 23044025.1572327
Operating income: -16163836.47798742
Net income: -43228616.35220125
Capital expenditures: 1666981.1320754716
Operating cash flow: -11958805.03144654
Depreciation & amortization: 4465094.339622641
Net tangible assets: 45534591.19496855
Owner earnings: -40430503.14465409
Return on net tangible assets (%): -88.7907458563536
Buffett classification: The Gruesome
Stock price: 1.86
Shares outstanding: 34577075
Book value: 43777672.95597483
P/B ratio: 1.4690904097318502
Market cap (USD): 64313359.5
Debt to equity: 0.9779761947519271
Current ratio: 1.831661528218044
Quick ratio: 1.1493696353872653
Interest coverage ratio: -19.447975785092698
COGS to revenue (%): 81.55215644415802
R&D to revenue (%): 1.4283988037097084
SG&A to revenue (%): 29.959368423172585
Free cash flow (dilution-adjusted): -15177672.955974841
Buyback yield (%): 0
Retained earnings: 8500943.396226415
Inventory turnover: 3.4362025987801643
Receivables turnover: 6.362570476678627
Capitalized R&D asset: 3156547.7505239504
ROCI (R&D-adjusted, %): -18.699241456520674
Rosenberg metric: -2.538244075979928
FCF margin (%): -12.150452636772835
Revenue growth (%): 2.869177846297518
Rule of 40 score: -9.281274790475317
Financial ratios for CUEX.V — annual report dated 2022-03-31
Total revenue: 0
Operating income: -59265.6
Net income: -59265.6
Capital expenditures: 0
Operating cash flow: -22172
Net tangible assets: 718235.2
Owner earnings: -59265.6
Return on net tangible assets (%): -8.251558820843089
Buffett classification: The Gruesome
Stock price: 0.72
Shares outstanding: 31833014
Book value: 718235.2000000001
P/B ratio: 31.91123197526381
Market cap (USD): 22919770.08
Debt to equity: 0
Current ratio: 8.118061667023445
Quick ratio: 8.118061667023445
Free cash flow (dilution-adjusted): -22172
Buyback yield (%): 0
Retained earnings: -185770.4
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -8.251558820843087
Rule of 40 score: 0
Financial ratios for CUEX.V — annual report dated 2023-03-31
Total revenue: 0
Operating income: -36144.444444444445
Net income: -18249.629629629628
Capital expenditures: 0
Operating cash flow: -66304.44444444444
Net tangible assets: 646782.9629629629
Owner earnings: -18249.629629629628
Return on net tangible assets (%): -2.8216002391322523
Buffett classification: The Gruesome
Stock price: 0.4888888888888889
Shares outstanding: 31833014
Book value: 646782.9629629629
P/B ratio: 24.061868873524467
Market cap (USD): 15562806.844444444
Debt to equity: 0
Current ratio: 39.047714497363714
Quick ratio: 39.047714497363714
Free cash flow (dilution-adjusted): -66304.44444444444
Buyback yield (%): 0
Retained earnings: -190259.25925925924
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -5.588342073647695
Rule of 40 score: 0
Financial ratios for CUEX.V — annual report dated 2023-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 0.42424242424242425
Shares outstanding: 31833014
Market cap (USD): 13504915.030303031
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for DOCS — annual report dated 2022-03-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 52.09
Shares outstanding: 128856933
Market cap (USD): 6712157639.97
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for DOCS — annual report dated 2023-03-31
Total revenue: 419052000
Gross profit: 365562000
Operating income: 125108000
Net income: 112818000
Capital expenditures: 1701000
Operating cash flow: 179602000
Depreciation & amortization: 10283000
Net tangible assets: 866340000
Owner earnings: 121400000
Return on net tangible assets (%): 14.012974121014842
Capex to operating income (%): 1.359625283754836
Buffett classification: The Great
Stock price: 32.38
P/E ratio: 36.98334920438228
Shares outstanding: 128856933
Book value: 966116000
P/B ratio: 4.3187231042028085
Market cap (USD): 4172387490.5400004
Debt to equity: 0.016185427008764994
Current ratio: 6.992143763395386
Quick ratio: 6.992143763395386
Effective tax rate (%): 15.273814172849889
COGS to revenue (%): 12.764525643595546
R&D to revenue (%): 19.135095405820756
SG&A to revenue (%): 38.24537288928343
Free cash flow (dilution-adjusted): 125584000
Buyback yield (%): 2.0449682632174984
Retained earnings: 217855000
Receivables turnover: 3.914654310723327
Capitalized R&D asset: 80186000
ROCI (R&D-adjusted, %): 16.57115829765883
FCF margin (%): 29.968595782862266
Rule of 40 score: 29.968595782862266
Financial ratios for DOCS — annual report dated 2024-03-31
Total revenue: 475422000
Gross profit: 424753000
Operating income: 171814000
Net income: 147582000
Capital expenditures: 147000
Operating cash flow: 184096000
Depreciation & amortization: 10265000
Net tangible assets: 806140000
Owner earnings: 157700000
Return on net tangible assets (%): 19.562358895477214
Capex to operating income (%): 0.08555763791076396
Buffett classification: The Great
Stock price: 26.91
P/E ratio: 23.495684209659714
Shares outstanding: 128856933
Book value: 901397000
P/B ratio: 3.846851128892153
Market cap (USD): 3467540067.03
Debt to equity: 0.016137173742535198
Current ratio: 6.199938879456706
Quick ratio: 6.199938879456706
Effective tax rate (%): 20.312955583633006
COGS to revenue (%): 10.657689379120024
R&D to revenue (%): 17.244258784826954
SG&A to revenue (%): 35.95879029577933
Free cash flow (dilution-adjusted): 127219000
Buyback yield (%): 8.095537313875582
Retained earnings: 79989000
Receivables turnover: 4.691726206923775
Capitalized R&D asset: 135707620
ROCI (R&D-adjusted, %): 18.705258668652895
Rosenberg metric: 0.7381712518394732
FCF margin (%): 26.75917395492846
Revenue growth (%): 13.45179118581942
Rule of 40 score: 40.21096514074788
Financial ratios for DOCS — quarterly report dated 2024-09-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 43.57
Shares outstanding: 128856933
Market cap (USD): 5614296570.81
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for DOCS — quarterly report dated 2024-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 53.39
Shares outstanding: 128856933
Market cap (USD): 6879671652.87
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for DOCS — annual report dated 2025-03-31
Total revenue: 570399000
Gross profit: 514525000
Operating income: 230104000
Net income: 223185000
Capital expenditures: 0
Operating cash flow: 273265000
Depreciation & amortization: 10659000
Net tangible assets: 991613000
Owner earnings: 233844000
Return on net tangible assets (%): 23.58218377532364
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 58.03
P/E ratio: 33.5038995541367
Shares outstanding: 128856933
Book value: 1082625000
P/B ratio: 6.9068863382888805
Market cap (USD): 7477567821.99
Debt to equity: 0.01144994804295116
Current ratio: 6.966855884856359
Quick ratio: 6.966855884856359
Effective tax rate (%): 15.323590338956041
COGS to revenue (%): 9.79559922089625
R&D to revenue (%): 16.311038413461453
SG&A to revenue (%): 33.55247817755641
Free cash flow (dilution-adjusted): 194354000
Buyback yield (%): 1.608718273958584
Retained earnings: 186888000
Receivables turnover: 4.4439518830733755
Capitalized R&D asset: 174427990
ROCI (R&D-adjusted, %): 18.56348651490461
Rosenberg metric: 1.0950075015552005
FCF margin (%): 34.073341643305824
Revenue growth (%): 19.977409543521336
Rule of 40 score: 54.050751186827156
Financial ratios for DOCS — quarterly report dated 2025-03-31
Total revenue: 138288000
Gross profit: 123821000
Operating income: 48680000
Net income: 62458000
Capital expenditures: 0
Operating cash flow: 98487000
Depreciation & amortization: 2829000
Net tangible assets: 991613000
Owner earnings: 65287000
Return on net tangible assets (%): 6.5839193314327265
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 58.03
P/E ratio: 29.93038450634827
Shares outstanding: 128856933
Book value: 1082625000
P/B ratio: 6.9068863382888805
Market cap (USD): 7477567821.99
Debt to equity: 0.01144994804295116
Current ratio: 6.966855884856359
Quick ratio: 6.966855884856359
Effective tax rate (%): -6.959619138952632
COGS to revenue (%): 10.461500636353119
R&D to revenue (%): 17.935757260210575
SG&A to revenue (%): 36.40084461413861
Free cash flow (dilution-adjusted): 78920000
Buyback yield (%): 0.3582448282344155
Retained earnings: 186888000
Receivables turnover: 1.0773953285444942
Capitalized R&D asset: 24803000
ROCI (R&D-adjusted, %): 5.75672379371882
FCF margin (%): 57.06930463959273
Rule of 40 score: 57.06930463959273
Financial ratios for DOCS — quarterly report dated 2025-06-30
Total revenue: 145913000
Gross profit: 130120000
Operating income: 54517000
Net income: 53320000
Capital expenditures: 1966000
Operating cash flow: 62101000
Depreciation & amortization: 2794000
Net tangible assets: 935586000
Owner earnings: 54148000
Return on net tangible assets (%): 5.78760263620875
Capex to operating income (%): 3.6062145752700996
Buffett classification: The Great
Stock price: 61.34
P/E ratio: 68.26931083815579
Shares outstanding: 128856933
Book value: 1025595000
P/B ratio: 7.706828007371331
Market cap (USD): 7904084270.22
Debt to equity: 0.011545493104003043
Current ratio: 6.467500875481515
Quick ratio: 6.467500875481515
Effective tax rate (%): 16.878419879339642
COGS to revenue (%): 10.823572951005051
R&D to revenue (%): 18.366423827897446
SG&A to revenue (%): 33.447328202421986
Free cash flow (dilution-adjusted): 38270000
Buyback yield (%): 1.5479971596582485
Retained earnings: 117110000
Receivables turnover: 1.0300007764906856
Capitalized R&D asset: 43417010
ROCI (R&D-adjusted, %): 5.89321337191457
Rosenberg metric: 0.2539612143692295
FCF margin (%): 26.227957755648912
Revenue growth (%): 5.5138551428902
Rule of 40 score: 31.741812898539113
Financial ratios for DOCS — quarterly report dated 2025-09-30
Total revenue: 168525000
Gross profit: 152100000
Operating income: 63681000
Net income: 62059000
Capital expenditures: 2369000
Operating cash flow: 93944000
Depreciation & amortization: 3469000
Net tangible assets: 971415000
Owner earnings: 63159000
Return on net tangible assets (%): 6.501752598014236
Capex to operating income (%): 3.7201048978502222
Buffett classification: The Great
Stock price: 73.15
P/E ratio: 53.002944544442386
Shares outstanding: 128856933
Book value: 1095531000
P/B ratio: 8.603941512335116
Market cap (USD): 9425884648.95
Debt to equity: 0.010286336032481053
Current ratio: 7.786411919868824
Quick ratio: 7.786411919868824
Effective tax rate (%): 14.916574123582722
COGS to revenue (%): 9.746328437917223
R&D to revenue (%): 17.921376650348613
SG&A to revenue (%): 34.545022993621124
Free cash flow (dilution-adjusted): 62101000
Buyback yield (%): 0.23226467133181794
Retained earnings: 157690000
Receivables turnover: 1.303303791007378
Capitalized R&D asset: 56342320
ROCI (R&D-adjusted, %): 5.678150415828305
Rosenberg metric: 0.8201798574573678
FCF margin (%): 36.849725560005936
Revenue growth (%): 15.496905690377142
Rule of 40 score: 52.346631250383076
Financial ratios for DOCS — quarterly report dated 2025-12-31
Total revenue: 185053000
Gross profit: 166352000
Operating income: 71896000
Net income: 61558000
Capital expenditures: 2375000
Operating cash flow: 60891000
Depreciation & amortization: 3989000
Net tangible assets: 857059000
Owner earnings: 63172000
Return on net tangible assets (%): 7.370787775404026
Capex to operating income (%): 3.30338266384778
Buffett classification: The Great
Stock price: 44.28
P/E ratio: 23.834186149418326
Shares outstanding: 128856933
Book value: 979298000
P/B ratio: 5.826403192123338
Market cap (USD): 5705784993.24
Debt to equity: 0.010918024952568064
Current ratio: 6.629738134643105
Quick ratio: 6.629738134643105
Effective tax rate (%): 23.81247060570806
COGS to revenue (%): 10.105753486838905
R&D to revenue (%): 18.69464423705641
SG&A to revenue (%): 32.34803002383101
Free cash flow (dilution-adjusted): 24970000
Buyback yield (%): 3.4505155773176672
Retained earnings: 20973000
Receivables turnover: 1.181775220481643
Capitalized R&D asset: 63674010
ROCI (R&D-adjusted, %): 7.09332375441869
Rosenberg metric: 0.4718892788557049
FCF margin (%): 13.493431611484278
Revenue growth (%): 9.807446966325472
Rule of 40 score: 23.300878577809748
Financial ratios for EMN.AX — annual report dated 2021-09-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 1.8201438848920863
Shares outstanding: 142954504
Market cap (USD): 260197766.2733813
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for EMN.AX — annual report dated 2022-09-30
Total revenue: 0
Gross profit: -139510.21897810217
Operating income: -9820927.007299269
Net income: -9822900
Capital expenditures: 4305766.423357664
Operating cash flow: -7051046.715328466
Depreciation & amortization: 139510.21897810217
Net tangible assets: 27218958.394160584
Owner earnings: -13989156.204379562
Return on net tangible assets (%): -51.394899105987555
Buffett classification: The Gruesome
Stock price: 0.9155844155844155
Shares outstanding: 142954504
Book value: 27218958.394160584
P/B ratio: 4.808667330491228
Market cap (USD): 130886915.99999999
Debt to equity: 0.00912821792603604
Current ratio: 9.095211028649409
Quick ratio: 9.095211028649409
Interest coverage ratio: -518.2247814197126
Free cash flow (dilution-adjusted): -15066442.335766422
Buyback yield (%): 0
Retained earnings: -35510232.84671532
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -35.921666579808225
Rule of 40 score: 0
Financial ratios for EMN.AX — annual report dated 2023-09-30
Total revenue: 0
Gross profit: 0
Operating income: -9621306.666666666
Net income: -8894911.85185185
Capital expenditures: 2619558.518518518
Operating cash flow: -8032739.999999999
Depreciation & amortization: 193461.48148148146
Net tangible assets: 20074124.444444444
Owner earnings: -11321008.888888888
Return on net tangible assets (%): -56.39602823136827
Buffett classification: The Gruesome
Stock price: 0.4487179487179487
Shares outstanding: 142954504
Book value: 20074124.444444444
P/B ratio: 3.1954694697842423
Market cap (USD): 64146251.79487179
Debt to equity: 0.0063622349582296255
Current ratio: 2.9951729824440854
Quick ratio: 2.9951729824440854
Interest coverage ratio: -516.3081448503399
Free cash flow (dilution-adjusted): -11846402.222222222
Buyback yield (%): 0
Retained earnings: -44931222.22222222
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -47.92889818579053
Rule of 40 score: 0
Financial ratios for EMN.AX — annual report dated 2024-09-30
Total revenue: 2382962.9629629627
Gross profit: -414074.07407407404
Operating income: -11281481.481481481
Net income: -13575555.555555554
Capital expenditures: 3067407.407407407
Operating cash flow: -10062962.962962963
Depreciation & amortization: 1924444.4444444443
Net tangible assets: 7270370.37037037
Owner earnings: -14718518.518518517
Return on net tangible assets (%): -202.44523688232294
Buffett classification: The Gruesome
Stock price: 0.16551724137931034
Shares outstanding: 142954504
Book value: 7270370.370370369
P/B ratio: 3.2545020321464335
Market cap (USD): 23661435.144827586
Debt to equity: 2.832195618950586
Current ratio: 0.35892898109002724
Quick ratio: 0.34015009995739526
Interest coverage ratio: -4.224687933425797
COGS to revenue (%): 117.37643767485235
SG&A to revenue (%): 189.92850481815356
Free cash flow (dilution-adjusted): -13924444.444444442
Buyback yield (%): 0
Retained earnings: -58506666.666666664
Inventory turnover: 6.589877835951134
Receivables turnover: 5.326158940397351
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -152.9884480160723
FCF margin (%): -584.3332297171277
Rule of 40 score: -584.3332297171277
Financial ratios for EMN.AX — quarterly report dated 2024-09-30
Capital expenditures: 76821.48148148147
Buffett classification: The Gruesome
Stock price: 0.16551724137931034
Shares outstanding: 142954504
Market cap (USD): 23661435.144827586
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for EMN.AX — quarterly report dated 2024-12-31
Operating income: -2775524.475524476
Capital expenditures: 67132.86713286713
Buffett classification: The Gruesome
Stock price: 0.08695652173913043
Shares outstanding: 142954504
Market cap (USD): 12430826.434782607
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for EMN.AX — quarterly report dated 2025-03-31
Total revenue: 611188.8111888112
Gross profit: -193706.2937062937
Operating income: -2232167.832167832
Net income: -2795804.195804196
Capital expenditures: 4895.104895104895
Operating cash flow: -1682517.4825174825
Depreciation & amortization: 732167.8321678322
Net tangible assets: -483916.0839160839
Owner earnings: -2068531.4685314687
Buffett classification: The Gruesome
Stock price: 0.16352201257861634
Shares outstanding: 142954504
Book value: -483916.0839160867
Market cap (USD): 23376208.201257862
Debt to equity: -42.26589595375699
Current ratio: 1.2671144407129942
Quick ratio: 1.0160165331955568
Interest coverage ratio: -3.108081791626095
COGS to revenue (%): 131.6933638443936
SG&A to revenue (%): 123.34096109839817
Free cash flow (dilution-adjusted): -1717482.5174825175
Buyback yield (%): 0
Retained earnings: -61648951.04895105
Inventory turnover: 1.184156378600823
Receivables turnover: 1.1021437578814628
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -11.217712177121772
FCF margin (%): -281.00686498855833
Rule of 40 score: -281.00686498855833
Financial ratios for EMN.AX — quarterly report dated 2025-06-30
Total revenue: 1118248.1751824818
Gross profit: 24087.59124087591
Operating income: -2116058.3941605836
Net income: -2666423.3576642335
Capital expenditures: 6569.34306569343
Operating cash flow: -856934.306569343
Depreciation & amortization: 628467.1532846715
Net tangible assets: 5169343.065693431
Owner earnings: -2044525.5474452556
Return on net tangible assets (%): -39.5509743010449
Buffett classification: The Gruesome
Stock price: 0.12418300653594772
Shares outstanding: 142954504
Book value: 5169343.065693431
P/B ratio: 3.434192677671276
Market cap (USD): 17752520.104575165
Debt to equity: 4.065235809093476
Current ratio: 4.224567474048443
Quick ratio: 4.003806228373702
Interest coverage ratio: -2.590705987488829
COGS to revenue (%): 97.84595300261095
SG&A to revenue (%): 80.54830287206265
Free cash flow (dilution-adjusted): -1140145.9854014597
Buyback yield (%): 0
Retained earnings: -67015328.46715328
Inventory turnover: 2.349529780564263
Receivables turnover: 2.4870129870129873
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -8.07588377858874
FCF margin (%): -101.95822454308092
Revenue growth (%): 82.96280211795754
Rule of 40 score: -18.99542242512338
Financial ratios for EMN.AX — quarterly report dated 2025-09-30
Total revenue: 678417.2661870504
Gross profit: -97122.30215827339
Operating income: -1913669.0647482015
Net income: -3423741.007194245
Capital expenditures: 7913.669064748202
Operating cash flow: -802158.273381295
Depreciation & amortization: 597122.3021582734
Net tangible assets: 2048920.8633093527
Owner earnings: -2834532.3741007196
Return on net tangible assets (%): -138.3426966292135
Buffett classification: The Gruesome
Stock price: 0.10526315789473684
Shares outstanding: 142954504
Book value: 2048920.8633093536
P/B ratio: 7.34427707569485
Market cap (USD): 15047842.526315788
Debt to equity: 10.785112359550558
Current ratio: 0.3253338836640231
Quick ratio: 0.3065833308764999
Interest coverage ratio: -2.8850325379609547
COGS to revenue (%): 114.31601272534463
SG&A to revenue (%): 119.19406150583245
Free cash flow (dilution-adjusted): -961870.5035971224
Buyback yield (%): 0
Retained earnings: -69474820.1438849
Inventory turnover: 1.6949685534591197
Receivables turnover: 1.4552469135802468
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -93.03952430919894
FCF margin (%): -141.78154825026513
Revenue growth (%): -39.33213742322069
Rule of 40 score: -181.11368567348583
Financial ratios for EMN.AX — annual report dated 2025-09-30
Total revenue: 3156115.107913669
Gross profit: -531654.6762589929
Operating income: -8108633.093525181
Net income: -12651798.56115108
Capital expenditures: 62589.92805755396
Operating cash flow: -5742446.043165468
Depreciation & amortization: 2807913.6690647486
Net tangible assets: 2048920.8633093527
Owner earnings: -9906474.820143884
Return on net tangible assets (%): -483.49719101123594
Buffett classification: The Gruesome
Stock price: 0.10526315789473684
Shares outstanding: 142954504
Book value: 2048920.8633093536
P/B ratio: 7.34427707569485
Market cap (USD): 15047842.526315788
Debt to equity: 10.785112359550558
Current ratio: 0.3253338836640231
Quick ratio: 0.3065833308764999
Interest coverage ratio: -2.6476391825229033
COGS to revenue (%): 116.84522452701162
SG&A to revenue (%): 81.83268748575337
Free cash flow (dilution-adjusted): -5141007.194244605
Buyback yield (%): 0
Retained earnings: -69474820.1438849
Inventory turnover: 8.059748427672956
Receivables turnover: 6.770061728395062
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -394.2287513116471
FCF margin (%): -162.89035787554138
Revenue growth (%): 32.44499209460535
Rule of 40 score: -130.44536578093604